Home Healthcare asia-pacific-migraine-treatment-market

Healthcare

Image

Asia-Pacific Migraine Treatment Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Jun 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Asia-Pacific Migraine Treatment Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 2.38 Billion
Diagram Market Size (Forecast Year) USD 4.67 Billion
Diagram CAGR %

Asia-Pacific Migraine Treatment Market, By Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/ Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others) – Industry Trends and Forecast to 2029

Market Analysis and Size

Migraine is a common and incapacitating brain disorder. Headache is responsible for 4.4 percent of all general practice visits, nearly 5% of all medical hospital admissions, and more than 20% of neurology outpatient consults. Migraine affects approximately 20% of people at some point in their lives; epidemiological studies show that 4.5 percent of the population in Western Europe suffers from headaches at least 15 days per month, while global studies suggest that about 1% of the world's population are suffering from chronic migraine.

Data Bridge Market Research analyses that the migraine treatment market which was USD 2.38 billion in 2021, would rocket up to USD 4.67 billion by 2029, and is expected to undergo a CAGR of 8.80% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/ Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others)

Countries Covered

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)

Market Players Covered

Pfizer Inc. (U.S), Eli Lilly and Company (U.S), Amgen Inc. (U.S), GSK plc. (U.K), Novartis AG (Switzerland), Bayer AG (Germany), Allergan (Ireland), Abbott (U.S), Allodynic Therapeutics, LLC (U.S), AOBiome (U.S), AstraZeneca (U.K), Aurobindo Pharma USA (U.S), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Dr. Reddy’s Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S)

Market Opportunities

  • Improved research and development (R&D) investment leading to pipeline products
  • Growing demand, and technological advancement for the treatment of acute migraine

Market Definition

Migraine is a life-threatening neurological condition marked by recurring attacks of severe throbbing head pain that can last up to three days. The headaches can last anywhere from four hours to three days and are usually unilateral. Other symptoms that are usually associated with pain include nausea, vomiting, increased sensitivity to light (photophobia), increased sensitivity to sound (phonophobia), tingling or numbness in the extremities or legs, sweating, and diarrhoea.

Migraine Treatment Market Dynamics

Drivers

  • Rise in the prevalence and diagnosis of migraine

A huge increase in migraine is a primary factor driving market expansion. Aside from that, the market is benefiting from improved reimbursement policies for migraine treatments and the rising demand for precision medicines. Additionally, rising demand for electrical nerve stimulating devices to treat migraines and the expected approval of new classes of late-stage pipeline drugs with higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are propelling market growth.

  • Significant advances are currently being made in the prophylactic treatment of CM

These significant advancements should prompt us to reconsider our approach to this devastating disease and empower us to remain vigilant and continue scientific clinical research, keeping in mind that only a common, shared clinical and scientific management strategy will improve CM detection, distinguish phenotypes and biological markers, shed light on neglected clinical governance areas, provide individualised healthcare and tailored therapy, and optimise the allocation of economic resources. It is our responsibility to guarantee that novel and evolving therapeutic options, such as OBT-A and anti-CGRP monoclonal antibodies, are fully utilised as part of a broader preventative culture in order to substantially reduce the human, societal, and economic consequences of this fatal disease.

  • Increase in focus of vendors on the emerging markets

Asia-Pacific and Latin America and the Caribbean are likely to drive market growth. Due to increased demand for better healthcare facilities and advances in healthcare infrastructure, Asia-Pacific is expected to grow significantly in the future. Furthermore, because the developed markets are somewhat saturated, this region presents exceptional potential for venture capitalists and investors.

Opportunities

Raised research and development (R&D) expenditure in migraine therapy leads to pipeline goods, which will result in manufacturers putting new medicines into the market, raising demand, and technological advancement for the treatment of acute migraine has increased demand. Several research projects are now underway, which will likely give manufacturers a competitive advantage in generating new, innovative, and enhanced migraine treatment drugs as well as other migraine therapy prospects.

Restraints/Challenges

However, use of alternative therapies such as homeopathy and limitations of current migraine therapies, a decline in clinical visits and procedural treatment of migraines due to social distancing norms expected to restraint the market growth in the forecast period 2022 to 2029.

This migraine treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Migraine Treatment Market

The neurologic indications of COVID-19 indicate that the virus entered the nervous system by the olfactory groove or the circulation. Numerous studies have connected COVID-19 mortality to cardiac and pulmonary disorders. Migraine also produces a higher rate of vascular problems, putting migraine sufferers at a higher risk of unsatisfactory COVID-19 results. COVID-19 acute symptoms such as fever, insomnia, and dehydration might set to a migraine episode. COVID-19 headaches were described as pulsing, pressing, or stabbing. They were mostly bilateral, lasted longer, were resistant to analgesia, and were more common in men. Migraine sufferers are especially sensitive to the pandemic's long-term and indirect effects, such as depression, tiredness from the virus, and anxiety.

Recent Development

  • In February 2022, Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, received a favourable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), according to Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. It is recommended for marketing authorization as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for the acute treatment of migraine with or without aura in adults, as well as the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
  • In January 2022, Elyxyb (celecoxib oral solution) is a novel fast-acting liquid from BioDelivery Sciences. It's one of the first FDA-approved ready-to-use oral treatments for individuals suffering from acute migraine with or without aura.

Asia-Pacific Migraine Treatment Market Scope

The migraine treatment market is segmented on the basis of type, treatment, route of administration, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Episodic
  • Migraine with Aura
  • Chronic
  • Others 

Treatment

  • Acute/Abortive Treatment
  • Preventive/prophylactic Treatment 
  • Non-Pharmacological Therapies and Devices

Route of Administration

  • Oral
  • Parenteral

 Product

  • Prescription
  • Over The Counter

Type

  • Branded
  • Generic

 End-User

  • Hospitals
  • Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others 

Migraine Treatment Market Regional Analysis/Insights

The migraine treatment market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, product, distribution channel and end-user as referenced above.

The countries covered in the migraine treatment market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

China is dominating the Asia-Pacific migraine treatment market because the pharmaceutical industry is one of leading industries in the country with growing number of investors. Focus on organic growth, rising urbanisation, and changes in disposable income are all major variables influencing the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Healthcare Infrastructure growth Installed base and New Technology Penetration

The migraine treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for migraine treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the migraine treatment market. The data is available for historic period 2010-2020.

Competitive Landscape and Migraine treatment Market Share Analysis

The migraine treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to migraine treatment market.

Some of the major players operating in the migraine treatment market are:

  • Pfizer Inc. (U.S)
  • Eli Lilly and Company (U.S)
  • Amgen Inc. (U.S)
  • GSK plc. (U.K)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Allergan (Ireland)
  • Abbott (U.S)
  • Allodynic Therapeutics, LLC (U.S)
  • AOBiome (U.S)
  • AstraZeneca (U.K)
  • Aurobindo Pharma USA (U.S)
  • Bausch Health Companies Inc. (Canada)
  • Biohaven Pharmaceuticals (U.S)
  • Boehringer Ingelheim International GmbH (Germany)
  • Catalent, Inc (U.S)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Impel Pharmaceuticals Inc. (U.S)
  • H. Lundbeck A/S (Denmark)
  • Merck & Co., Inc (U.S)

SKU-

LIST OF TABLES

TABLE 1 GENERIC DRUGS FOR MIGRAINE TREATMENT

TABLE 2 PIPELINE DRUGS FOR MIGRAINE TREATMENT

TABLE 3 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY PIPELINE ANALYSIS

TABLE 4 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 5 ASIA PACIFIC EPISODIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 6 ASIA PACIFIC MIGRAINE WITH AURA IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 ASIA PACIFIC CHRONIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 8 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 9 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 10 ASIA PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 11 ASIA PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 12 ASIA PACIFIC NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TRAETMENT, 2018-2027 (USD MILLION)

TABLE 13 ASIA PACIFIC TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 14 ASIA PACIFIC OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 15 ASIA PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 16 ASIA PACIFIC ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 17 ASIA PACIFIC ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 18 ASIA PACIFIC ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 19 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY TRATMENT, 2018-2027 (USD MILLION)

TABLE 20 ASIA PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 ASIA PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 22 ASIA PACIFIC ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 23 ASIA PACIFIC CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 24 ASIA PACIFIC SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 25 ASIA PACIFIC ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 26 ASIA PACIFIC NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 27 ASIA PACIFIC BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 28 ASIA PACIFIC BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 29 ASIA PACIFIC CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 30 ASIA PACIFIC ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 31 ASIA PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 ASIA PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 33 ASIA PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 ASIA PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 35 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 36 ASIA PACIFIC ORAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 ASIA PACIFIC PARENTERAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 38 ASIA PACIFIC NASAL SPRAYS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 40 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 41 ASIA PACIFIC PRESCRIPTION IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 42 ASIA PACIFIC OVER THE COUNTER IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 43 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 44 ASIA PACIFIC GENERIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 45 ASIA PACIFIC BRANDED IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 46 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 47 ASIA PACIFIC HOSPITALS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 48 ASIA PACIFIC CLINICS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 49 ASIA PACIFIC HOMECARE IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 50 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 51 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 52 ASIA PACIFIC HOSPITAL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 53 ASIA PACIFIC RETAIL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 54 ASIA PACIFIC ONLINE PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 55 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 56 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 57 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 58 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 59 ASIA-PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 60 ASIA-PACIFIC NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 61 ASIA-PACIFIC TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 62 ASIA-PACIFIC OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 63 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 64 ASIA-PACIFIC ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 65 ASIA-PACIFIC ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 66 ASIA-PACIFIC ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 67 ASIA-PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 68 ASIA-PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 69 ASIA-PACIFIC ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 70 ASIA-PACIFIC CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 71 ASIA-PACIFIC SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 72 ASIA-PACIFIC ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 73 ASIA-PACIFIC NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 74 ASIA-PACIFIC BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 75 ASIA-PACIFIC BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 76 ASIA-PACIFIC CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 77 ASIA-PACIFIC ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 78 ASIA-PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 79 ASIA-PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 80 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 81 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 82 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 83 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 84 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 85 CHINA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 86 CHINA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 87 CHINA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 88 CHINA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 89 CHINA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 90 CHINA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 91 CHINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 92 CHINA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 93 CHINA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 94 CHINA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 95 CHINA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 96 CHINA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 97 CHINA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 98 CHINA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)

TABLE 99 CHINA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 100 CHINA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 101 CHINA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 102 CHINA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 103 CHINA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 104 CHINA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 105 CHINA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 106 CHINA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 107 CHINA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 108 CHINA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 109 CHINA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 110 CHINA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 111 CHINA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 112 CHINA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 113 JAPAN MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 114 JAPAN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 115 JAPAN ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 116 JAPAN NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 117 JAPAN TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 118 JAPAN OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 119 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 120 JAPAN ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 121 JAPAN ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 122 JAPAN ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 123 JAPAN OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 124 JAPAN PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 125 JAPAN ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 126 JAPAN CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 127 JAPAN SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 128 JAPAN ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 129 JAPAN NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 130 JAPAN BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 131 JAPAN BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 132 JAPAN CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 133 JAPAN ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 134 JAPAN NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 135 JAPAN DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 136 JAPAN MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 137 JAPAN MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 138 JAPAN MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 139 JAPAN MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 140 JAPAN MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 141 INDIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 142 INDIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 143 INDIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 144 INDIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 145 INDIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 146 INDIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 147 INDIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 148 INDIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 149 INDIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 150 INDIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 151 INDIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 152 INDIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 153 INDIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 154 INDIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 155 INDIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 156 INDIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 157 INDIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 158 INDIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 159 INDIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 160 INDIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 161 INDIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 162 INDIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 163 INDIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 164 INDIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 165 INDIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 166 INDIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 167 INDIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 168 INDIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 169 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 170 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 171 SOUTH KOREA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 172 SOUTH KOREA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 173 SOUTH KOREA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 174 SOUTH KOREA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 175 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 176 SOUTH KOREA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 177 SOUTH KOREA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 178 SOUTH KOREA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 179 SOUTH KOREA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 180 SOUTH KOREA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 181 SOUTH KOREA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 182 SOUTH KOREA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 183 SOUTH KOREA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 184 SOUTH KOREA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 185 SOUTH KOREA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 186 SOUTH KOREA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 187 SOUTH KOREA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 188 SOUTH KOREA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 189 SOUTH KOREA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 190 SOUTH KOREA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 191 SOUTH KOREA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 192 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 193 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 194 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 195 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 196 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 197 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 198 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 199 AUSTRALIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 200 AUSTRALIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 201 AUSTRALIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 202 AUSTRALIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 203 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 204 AUSTRALIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 205 AUSTRALIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 206 AUSTRALIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 207 AUSTRALIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 208 AUSTRALIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 209 AUSTRALIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 210 AUSTRALIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 211 AUSTRALIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 212 AUSTRALIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 213 AUSTRALIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 214 AUSTRALIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 215 AUSTRALIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 216 AUSTRALIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 217 AUSTRALIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 218 AUSTRALIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 219 AUSTRALIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 220 AUSTRALIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 221 AUSTRALIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 222 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 223 AUSTRALIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 224 AUSTRALIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 225 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 226 SINGAPORE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 227 SINGAPORE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 228 SINGAPORE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 229 SINGAPORE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 230 SINGAPORE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 231 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 232 SINGAPORE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 233 SINGAPORE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 234 SINGAPORE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 235 SINGAPORE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 236 SINGAPORE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 237 SINGAPORE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 238 SINGAPORE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 239 SINGAPORE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 240 SINGAPORE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 241 SINGAPORE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 242 SINGAPORE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 243 SINGAPORE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 244 SINGAPORE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 245 SINGAPORE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 246 SINGAPORE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 247 SINGAPORE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 248 SINGAPORE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 249 SINGAPORE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 250 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 251 SINGAPORE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 252 SINGAPORE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 253 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 254 INDONESIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 255 INDONESIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 256 INDONESIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 257 INDONESIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 258 INDONESIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 259 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 260 INDONESIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 261 INDONESIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 262 INDONESIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 263 INDONESIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 264 INDONESIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 265 INDONESIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 266 INDONESIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 267 INDONESIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 268 INDONESIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 269 INDONESIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 270 INDONESIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 271 INDONESIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 272 INDONESIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 273 INDONESIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 274 INDONESIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 275 INDONESIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 276 INDONESIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 277 INDONESIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 278 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 279 INDONESIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 280 INDONESIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 281 THAILAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 282 THAILAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 283 THAILAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 284 THAILAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 285 THAILAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 286 THAILAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 287 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 288 THAILAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 289 THAILAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 290 THAILAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 291 THAILAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 292 THAILAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 293 THAILAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 294 THAILAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 295 THAILAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 296 THAILAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 297 THAILAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 298 THAILAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 299 THAILAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 300 THAILAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 301 THAILAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 302 THAILAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 303 THAILAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 304 THAILAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 305 THAILAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 306 THAILAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 307 THAILAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 308 THAILAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 309 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 310 MALAYSIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 311 MALAYSIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 312 MALAYSIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 313 MALAYSIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 314 MALAYSIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 315 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 316 MALAYSIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 317 MALAYSIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 318 MALAYSIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 319 MALAYSIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 320 MALAYSIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 321 MALAYSIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 322 MALAYSIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 323 MALAYSIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 324 MALAYSIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 325 MALAYSIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 326 MALAYSIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 327 MALAYSIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 328 MALAYSIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 329 MALAYSIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 330 MALAYSIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 331 MALAYSIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 332 MALAYSIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 333 MALAYSIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 334 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 335 MALAYSIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 336 MALAYSIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 337 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 338 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 339 PHILIPPINES ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 340 PHILIPPINES NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 341 PHILIPPINES TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 342 PHILIPPINES OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 343 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 344 PHILIPPINES ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 345 PHILIPPINES ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 346 PHILIPPINES ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 347 PHILIPPINES OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 348 PHILIPPINES PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 349 PHILIPPINES ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 350 PHILIPPINES CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 351 PHILIPPINES SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 352 PHILIPPINES ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 353 PHILIPPINES NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 354 PHILIPPINES BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 355 PHILIPPINES BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 356 PHILIPPINES CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 357 PHILIPPINES ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 358 PHILIPPINES NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 359 PHILIPPINES DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 360 PHILIPPINES MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 361 PHILIPPINES MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 362 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 363 PHILIPPINES MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 364 PHILIPPINES MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 365 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 366 VIETNAM MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 367 VIETNAM ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 368 VIETNAM NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 369 VIETNAM TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 370 VIETNAM OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 371 VIETNAM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 372 VIETNAM ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 373 VIETNAM ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 374 VIETNAM ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 375 VIETNAM OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 376 VIETNAM PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 377 VIETNAM ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 378 VIETNAM CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 379 VIETNAM SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 380 VIETNAM ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 381 VIETNAM NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 382 VIETNAM BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 383 VIETNAM BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 384 VIETNAM CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 385 VIETNAM ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 386 VIETNAM NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 387 VIETNAM DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 388 VIETNAM MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 389 VIETNAM MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 390 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 391 VIETNAM MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 392 VIETNAM MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 393 REST OF ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 394 SUBSIDIARIES OF JANSSEN ASIA PACIFIC SERVICES, LLC

 

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The major Asia-Pacific Migraine Treatment Market drivers for the Migraine Treatment market are Rise in the prevalence and diagnosis of migraine, and Significant advances are currently being made in the prophylactic treatment of CM.
The Asia-Pacific Migraine Treatment Market is to grow at a CAGR of 8.40% during the forecast by 2029.
The major players operating in the Asia-Pacific Migraine Treatment Market are Pfizer Inc. (U.S), Eli Lilly and Company (U.S), Amgen Inc. (U.S), GSK plc. (U.K), Novartis AG (Switzerland), Bayer AG (Germany), Allergan (Ireland), Abbott (U.S), Allodynic Therapeutics, LLC (U.S), AOBiome (U.S), AstraZeneca (U.K), Aurobindo Pharma USA (U.S), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Dr. Reddy’s Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S).
The Asia-Pacific Migraine Treatment Market value is expected USD 4.67 billion by 2029.

BROWSE RELATED REPORTS

Global Migraine Treatment Market – Industry Trends and Forecast to 2029
Middle East and Africa Migraine Treatment Market – Industry Trends and Forecast to 2030
Europe Migraine Treatment Market – Industry Trends and Forecast to 2030
North America Migraine Treatment Market – Industry Trends and Forecast to 2030

BROWSE RELATED Blogs

Migraine Treatment: Transforming Lives and Easing the Burden of Pain
Global Migraine Treatment Market is Expected to Reach an Estimated Valuation of USD 12,943.53 Million by 2027

BROWSE RELATED Press Release

Growing Awareness about Migraine is increasing the Growth of the Market
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future